Pharmacy

The FINANCIAl -- TOKYO – May 29, 2018 – Astellas Pharma Inc. announced, that the U.S. Food and Drug Administration has accepted, with Priority Review, the company’s New Drug Application for gilteritinib for the treatment of adult patients who have relapsed or refractory Acute Myeloid Leukemia with a FLT3 mutation as detected by an FDA-approved test. Currently, there are no FLT3-targeting ...

More Articles ...

More Articles ...

The FINANCIAL -- Commenting on the Group’s sales, Roche CEO Severin Schwan said: “We have started the year with strong sales growth in both our Pharmaceuticals and Diagnostics Divisions. I am ...

The FINANCIAL -- Bayer announced on May 11 that Eylea (aflibercept solution for injection into the eye) has been approved by the Chinese regulatory authorities for the treatment of visual impairment ...